TGFB1 and Hepatic fibrosis: In CCl4-induced liver fibrosis mouse model, the VD60-treated group showed that a-SMA expression, TGF-β, and fibronectin mRNA levels, the fibrotic area, and hepatic hydroxyproline (HYP) deposition all decreased compared with the vehicle group, suggesting that VD60 could effectively ameliorate liver fibrosis.